The regular Pharma Readiness reports produced by Diaceutics aim to capture a snapshot of the diagnostic and precision medicine industries at certain times in a fast-evolving landscape. Pharma Readiness for Diagnostic Integration 2017 is no exception and discusses such vital topics as:
Production of this year’s report involved analysing 23 main pharma companies and the PM credentials of over 1000 therapies on the market and in the pipeline, providing a 360° view of Dx-dependent therapy assets. The benchmarking process is continually being refined to provide the most important industry insights. New analytical additions for 2017 include:
Being at the heart of the diagnostics space, Diaceutics is perfectly placed to not only analyse and comment on the precision medicine world in real-time but to make informed and thought-provoking predictions for the years ahead. So in addition to concise predictions around segmentation, partnering, the role of laboratories and Dx-enablement strategies, the 2017 report also contains a series of specially commissioned opinion pieces looking at the key trends likely to shape the pharma/Dx interface and PM marketplace to 2020 and beyond.
For an informed view of the current diagnostic landscape, the companies forging ahead and a look ahead at future trends, download Pharma Readiness for Diagnostic Integration 2017.